[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100574990":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":12,"centralContacts":25,"locations":31,"responsibleParty":49,"collaborators":53,"id":58,"slug":12,"hasResults":59,"nctId":60,"briefTitle":61,"officialTitle":61,"acronym":62,"eligibilityCriteria":63,"healthyVolunteers":59,"sex":64,"minAge":65,"maxAge":12,"enrollmentInfo":66,"targetDuration":12,"studyType":69,"phases":70,"briefSummary":72,"conditions":73,"keywords":77,"overallStatus":34,"whyStopped":12,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},{"fullName":5,"class":6},"Erasmus Medical Center","OTHER",[8,13],{"label":9,"type":10,"description":11,"interventionNames":12},"Control","NO_INTERVENTION","This arm will receive standard of care according to local protocol.",null,{"label":14,"type":15,"description":16,"interventionNames":17},"Intervention","EXPERIMENTAL","This arm will be treated with double dosages of beta-lactam antibiotics the first 48 hours after inclusion.",[18],"Drug: Double dosing of beta-lactam antibiotic",[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":12},"DRUG","Double dosing of beta-lactam antibiotic","This arm will receive double dosing of beta-lactam antibiotics for the first 48 hours after inclusion.",[14],[26],{"name":27,"role":28,"phone":29,"phoneExt":12,"email":30},"Birgit C.P. Koch, PharmD","CONTACT","0031107033202","b.koch@erasmusmc.nl",[32],{"facility":33,"status":34,"city":35,"state":12,"zip":12,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"Maasstad Ziekenhuis","RECRUITING","Rotterdam","Netherlands","NL",{"type":39,"coordinates":40},"Point",[41,42],4.47917,51.9225,{"lat":42,"lon":41},[45],{"name":46,"role":28,"phone":47,"phoneExt":12,"email":48},"Dr. Den Uil","0031102913474","uilc@maasstadziekenhuis.nl",{"type":50,"investigatorFullName":51,"investigatorTitle":52,"investigatorAffiliation":5,"oldNameTitle":12,"oldOrganization":12},"PRINCIPAL_INVESTIGATOR","Birgit Koch","Principal Investigator",[54,56],{"name":55,"class":6},"Maasstad Hospital",{"name":57,"class":6},"Albert Schweitzer Hospital","100574990",false,"NCT06766461","Beta-Lactam Antibiotics InitiaL ExpoSure OptimisEd in CriticallY Ill Patients with SEpsis","BULLSEYE","Inclusion Criteria:\n\n* ≥18 years of age\n* Receiving intravenous antibiotic therapy of the target drugs (including continuous infusion of beta-lactam antibiotics)\n* Primary infection\n* Admitted to the ICU\n* Meeting the Sepsis-3 criteria for septic shock: sepsis in addition to shock requiring the start of vasopressors to maintain a mean arterial pressure 65 mmHg or greater, and a serum lac tate level greater than 2.0 mmol\u002FL following \"adequate fluid resuscitation\".\n\nExclusion Criteria:\n\n* Patient or legal representative not available to give informed consent within 72 hours after admittance\n* Pregnancy\n* Admittance for burn wounds\n* Patients receiving target antibiotics only as prophylaxis within the context of Selective Diges tive tract Decontamination (SDD)\n* Enrolment in another interventional trial\n* Patient received the study antibiotic for more than 24 hours before inclusion\n* Patient receiving extracorporeal membrane oxygenation (ECMO)\n* Patient is already treated with a double dose of antibiotics based on suspected infection","ALL","18 Years",{"count":67,"type":68},980,"ESTIMATED","INTERVENTIONAL",[71],"PHASE4","The aim of this study is to investigate if an initial short double dose of beta-lactam antibiotics will reduce mortality in critically ill patients with sepsis.",[74,75,76],"Sepsis - to Reduce Mortality in the Intensive Care Unit","Sepsis","Septic Shock",[78,79,80,81,82],"sepsis","intensive care","critically ill","antibiotic","septic shock","2025-01-08",{"date":85,"type":86},"2025-01-09","ACTUAL",{"date":88,"type":86},"2025-01-03",{"date":90,"type":68},"2027-12-01",{"name":5,"class":6},1]